


the specification. Claims 16-25 draw support from, e.g., the exemplary embodiments, substituents, and examples described at pages 10-73.

In the outstanding Office Action, the Examiner required Applicant to elect a species for examination. In response to this requirement, Applicant hereby elects the following species:




The elected species is disclosed in the specification at the bottom of page 58 (compound 25', for which data are given on page 59, last paragraph), and on page 70, first row, first compound. All of the pending claims read on the elected species. This election is without traverse, insofar that Applicant understands that if the elected species is found allowable, the Examiner will expand the search to encompass generic subject matter defined in the claims.

In view of the foregoing, Applicant requests prompt action on the merits.

If any fees other than those submitted herewith are due in connection with this response, including the fee for any required extension of time (for which Applicant hereby petitions), please charge all such required fees to Deposit Account No. 500329.

Respectfully submitted,

  
Janet R. Elliott  
Registration No. 33,594  
Agent for Alanex Corporation,  
a wholly owned subsidiary of  
Agouron Pharmaceuticals, Inc.  
10350 North Torrey Pines Road  
La Jolla, California 92037

September 22, 1998

0035-01-US